{"id":"https://openalex.org/W4284890639","doi":"https://doi.org/10.1158/1535-7163.mct-22-0145","title":"Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody\u2013Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine Dimer","display_name":"Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody\u2013Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine Dimer","publication_year":2022,"publication_date":"2022-07-06","ids":{"openalex":"https://openalex.org/W4284890639","doi":"https://doi.org/10.1158/1535-7163.mct-22-0145","pmid":"https://pubmed.ncbi.nlm.nih.gov/35793464"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.mct-22-0145","doi":"https://doi.org/10.1158/1535-7163.mct-22-0145","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-22-0145","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5070013000","display_name":"Stephen J. Gregson","orcid":"https://orcid.org/0000-0002-6859-9772","observed_orcids":["https://orcid.org/0000-0002-6859-9772"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Stephen J. Gregson","raw_affiliation_strings":["1TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0002-6859-9772","affiliations":[{"raw_affiliation_string":"1TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021462287","display_name":"Kathryn Pugh","orcid":"https://orcid.org/0000-0003-0552-3508","observed_orcids":["https://orcid.org/0000-0003-0552-3508"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Kathryn Pugh","raw_affiliation_strings":["1TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0003-0552-3508","affiliations":[{"raw_affiliation_string":"1TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043702380","display_name":"Neki Patel","orcid":"https://orcid.org/0000-0002-6045-9089","observed_orcids":["https://orcid.org/0000-0002-6045-9089"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Neki Patel","raw_affiliation_strings":["1TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0002-6045-9089","affiliations":[{"raw_affiliation_string":"1TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003565644","display_name":"Shameen Afif-Rider","orcid":"https://orcid.org/0000-0003-0932-1794","observed_orcids":["https://orcid.org/0000-0003-0932-1794"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shameen Afif-Rider","raw_affiliation_strings":["2AstraZeneca, One Medimmune Way, Gaithersburg, Maryland"],"raw_orcid":"https://orcid.org/0000-0003-0932-1794","affiliations":[{"raw_affiliation_string":"2AstraZeneca, One Medimmune Way, Gaithersburg, Maryland","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048240683","display_name":"Balakumar Vijayakrishnan","orcid":"https://orcid.org/0000-0002-0329-8565","observed_orcids":["https://orcid.org/0000-0002-0329-8565"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Balakumar Vijayakrishnan","raw_affiliation_strings":["1TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0002-0329-8565","affiliations":[{"raw_affiliation_string":"1TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043092566","display_name":"Kathleen Santos","orcid":"https://orcid.org/0000-0002-0544-0975","observed_orcids":["https://orcid.org/0000-0002-0544-0975"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Kathleen Santos","raw_affiliation_strings":["1TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0002-0544-0975","affiliations":[{"raw_affiliation_string":"1TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061663800","display_name":"Jitka Riedl","orcid":"https://orcid.org/0000-0002-5191-9645","observed_orcids":["https://orcid.org/0000-0002-5191-9645"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Jitka Riedl","raw_affiliation_strings":["1TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0002-5191-9645","affiliations":[{"raw_affiliation_string":"1TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000709034","display_name":"Ian Hutchinson","orcid":"https://orcid.org/0000-0001-6118-0509","observed_orcids":["https://orcid.org/0000-0001-6118-0509"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Ian Hutchinson","raw_affiliation_strings":["1TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0001-6118-0509","affiliations":[{"raw_affiliation_string":"1TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042410729","display_name":"Gyoung\u2010Dong Kang","orcid":"https://orcid.org/0000-0002-7465-9276","observed_orcids":["https://orcid.org/0000-0002-7465-9276"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Gyoung-Dong Kang","raw_affiliation_strings":["1TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0002-7465-9276","affiliations":[{"raw_affiliation_string":"1TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053050254","display_name":"K. Phin Chooi","orcid":"https://orcid.org/0000-0001-8657-1522","observed_orcids":["https://orcid.org/0000-0001-8657-1522"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"K. Phin Chooi","raw_affiliation_strings":["1TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0001-8657-1522","affiliations":[{"raw_affiliation_string":"1TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085183749","display_name":"Rhiannon Beard","orcid":"https://orcid.org/0000-0001-9499-0743","observed_orcids":["https://orcid.org/0000-0001-9499-0743"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Rhiannon Beard","raw_affiliation_strings":["1TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0001-9499-0743","affiliations":[{"raw_affiliation_string":"1TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013463645","display_name":"Lauren R. Adams","orcid":"https://orcid.org/0000-0002-0906-468X","observed_orcids":["https://orcid.org/0000-0002-0906-468X"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Lauren Adams","raw_affiliation_strings":["1TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0002-0906-468X","affiliations":[{"raw_affiliation_string":"1TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084252361","display_name":"Conor St. J. Barry","orcid":"https://orcid.org/0000-0002-1400-6767","observed_orcids":["https://orcid.org/0000-0002-1400-6767"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Conor S. Barry","raw_affiliation_strings":["1TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0002-1400-6767","affiliations":[{"raw_affiliation_string":"1TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012679547","display_name":"Kathryn Ball","orcid":"https://orcid.org/0000-0002-5654-8732","observed_orcids":["https://orcid.org/0000-0002-5654-8732"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Kathryn Ball","raw_affiliation_strings":["3AstraZeneca, Granta Park, Cambridge, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0002-5654-8732","affiliations":[{"raw_affiliation_string":"3AstraZeneca, Granta Park, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044830291","display_name":"Luke A. Masterson","orcid":"https://orcid.org/0000-0002-5366-4025","observed_orcids":["https://orcid.org/0000-0002-5366-4025"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Luke A. Masterson","raw_affiliation_strings":["1TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0002-5366-4025","affiliations":[{"raw_affiliation_string":"1TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053107298","display_name":"Mary McFarlane","orcid":"https://orcid.org/0000-0002-1211-8650","observed_orcids":["https://orcid.org/0000-0002-1211-8650"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Mary McFarlane","raw_affiliation_strings":["3AstraZeneca, Granta Park, Cambridge, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0002-1211-8650","affiliations":[{"raw_affiliation_string":"3AstraZeneca, Granta Park, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055669649","display_name":"John Anthony Hartley","orcid":"https://orcid.org/0000-0003-3737-9897","observed_orcids":["https://orcid.org/0000-0003-3737-9897"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"John A. Hartley","raw_affiliation_strings":["1TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0003-3737-9897","affiliations":[{"raw_affiliation_string":"1TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5051368970","display_name":"Philip W. Howard","orcid":"https://orcid.org/0000-0001-6392-2289","observed_orcids":["https://orcid.org/0000-0001-6392-2289","https://orcid.org/0000-0001-7828-1154"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Philip W. Howard","raw_affiliation_strings":["1TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0001-6392-2289","affiliations":[{"raw_affiliation_string":"1TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5055669649","https://openalex.org/A5070013000"],"corresponding_institution_ids":["https://openalex.org/I105036370"],"apc_list":null,"apc_paid":null,"fwci":0.7392,"has_fulltext":false,"cited_by_count":10,"citation_normalized_percentile":{"value":0.58313475,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":96},"biblio":{"volume":"21","issue":"9","first_page":"1439","last_page":"1448"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T13105","display_name":"Synthesis and pharmacology of benzodiazepine derivatives","score":0.6151999831199646,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},"topics":[{"id":"https://openalex.org/T13105","display_name":"Synthesis and pharmacology of benzodiazepine derivatives","score":0.6151999831199646,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.3310999870300293,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12477","display_name":"Toxin Mechanisms and Immunotoxins","score":0.011699999682605267,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.9990000128746033},{"id":"https://openalex.org/keywords/pyrrolobenzodiazepine-dimer","display_name":"pyrrolobenzodiazepine dimer","score":0.9879999756813049},{"id":"https://openalex.org/keywords/drug-to-antibody-ratio","display_name":"drug-to-antibody ratio","score":0.9589999914169312},{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":0.7839999794960022},{"id":"https://openalex.org/keywords/anti-her2","display_name":"anti-HER2","score":0.8939999938011169},{"id":"https://openalex.org/keywords/anti-cd22","display_name":"anti-CD22","score":0.9879999756813049},{"id":"https://openalex.org/keywords/hematologic-malignancies","display_name":"hematologic malignancies","score":0.675000011920929},{"id":"https://openalex.org/keywords/solid-tumors","display_name":"solid tumors","score":0.8830000162124634},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8080000281333923},{"id":"https://openalex.org/keywords/toxicity","display_name":"toxicity","score":0.5339999794960022},{"id":"https://openalex.org/keywords/xenograft-models","display_name":"xenograft models","score":0.7699999809265137},{"id":"https://openalex.org/keywords/topoisomerase-inhibitors","display_name":"topoisomerase inhibitors","score":0.6589999794960022}],"concepts":[{"id":"https://openalex.org/C57992300","wikidata":"https://www.wikidata.org/wiki/Q2066956","display_name":"Potency","level":3,"score":0.8822920322418213},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.7306259870529175},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.688567578792572},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.569668173789978},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5399987101554871},{"id":"https://openalex.org/C197336794","wikidata":"https://www.wikidata.org/wiki/Q5161150","display_name":"Conjugate","level":2,"score":0.5198155641555786},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.5189630389213562},{"id":"https://openalex.org/C2777325958","wikidata":"https://www.wikidata.org/wiki/Q1069596","display_name":"Antibody-drug conjugate","level":4,"score":0.5167269110679626},{"id":"https://openalex.org/C19831878","wikidata":"https://www.wikidata.org/wiki/Q659446","display_name":"Therapeutic index","level":3,"score":0.47076037526130676},{"id":"https://openalex.org/C2780557392","wikidata":"https://www.wikidata.org/wiki/Q523796","display_name":"Linker","level":2,"score":0.45119449496269226},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.39552217721939087},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.34824955463409424},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.2902982234954834},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.24902698397636414},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.14903602004051208},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.1296556293964386},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.1063501238822937},{"id":"https://openalex.org/C134306372","wikidata":"https://www.wikidata.org/wiki/Q7754","display_name":"Mathematical analysis","level":1,"score":0.0},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0},{"id":"https://openalex.org/C33923547","wikidata":"https://www.wikidata.org/wiki/Q395","display_name":"Mathematics","level":0,"score":0.0},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.0},{"id":"https://openalex.org/C111919701","wikidata":"https://www.wikidata.org/wiki/Q9135","display_name":"Operating system","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D001569","descriptor_name":"Benzodiazepines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011758","descriptor_name":"Pyrroles","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018796","descriptor_name":"Immunoconjugates","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1158/1535-7163.mct-22-0145","doi":"https://doi.org/10.1158/1535-7163.mct-22-0145","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-22-0145","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},{"id":"pmid:35793464","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/35793464","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular cancer therapeutics","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":39,"referenced_works":["https://openalex.org/W1953598751","https://openalex.org/W1978653570","https://openalex.org/W1980048870","https://openalex.org/W1980570719","https://openalex.org/W1996363339","https://openalex.org/W2023034663","https://openalex.org/W2037457483","https://openalex.org/W2043267554","https://openalex.org/W2110719368","https://openalex.org/W2116375371","https://openalex.org/W2158998685","https://openalex.org/W2171368669","https://openalex.org/W2513682949","https://openalex.org/W2549780925","https://openalex.org/W2560431464","https://openalex.org/W2592363471","https://openalex.org/W2636487951","https://openalex.org/W2774586064","https://openalex.org/W2781864644","https://openalex.org/W2783482091","https://openalex.org/W2839071055","https://openalex.org/W2887583157","https://openalex.org/W2904320090","https://openalex.org/W2907492481","https://openalex.org/W2921348012","https://openalex.org/W2935912602","https://openalex.org/W2951939015","https://openalex.org/W2958762925","https://openalex.org/W2973098277","https://openalex.org/W2982411421","https://openalex.org/W2986702822","https://openalex.org/W2999186793","https://openalex.org/W3004080772","https://openalex.org/W3009885756","https://openalex.org/W3034835401","https://openalex.org/W3035644303","https://openalex.org/W3150901539","https://openalex.org/W3204247219","https://openalex.org/W6747501353"],"related_works":["https://openalex.org/W2604196310","https://openalex.org/W3034835401","https://openalex.org/W2315176717","https://openalex.org/W3046548788","https://openalex.org/W2951939015","https://openalex.org/W2052768531","https://openalex.org/W2080228517","https://openalex.org/W2002329021","https://openalex.org/W2636487951","https://openalex.org/W4283791096"],"abstract_inverted_index":{"Antibody-drug":[0],"conjugate":[1],"(ADC)":[2],"research":[3],"has":[4,33],"typically":[5],"focused":[6,66],"on":[7,67],"the":[8,79,98,106,120,124,127,141,147],"release":[9,28,39,78],"of":[10,105,111,175,205,222,236],"highly":[11],"potent":[12],"cytotoxic":[13,41],"agents":[14],"to":[15,43,170,224],"achieve":[16],"antitumor":[17,152],"efficacy.":[18],"However,":[19],"recently":[20],"approved":[21],"ADCs":[22,37,55,76,117,144,241],"trastuzumab":[23,171],"deruxtecan":[24],"and":[25,48,157,177,179,183,189,199,226,245],"sacituzumab":[26],"govitecan":[27],"lower-potency":[29,40],"topoisomerase":[30],"inhibitors.":[31],"This":[32],"prompted":[34],"interest":[35],"in":[36,60,131,139,154,213,216,240],"that":[38,77,233,242],"drugs":[42,130],"potentially":[44],"enhance":[45],"therapeutic":[46],"index":[47],"reduce":[49],"unwanted":[50],"toxicity.":[51],"Pyrrolobenzodiazepine":[52],"(PBD)":[53],"dimer":[54,82],"have":[56,65],"been":[57],"widely":[58],"investigated":[59],"human":[61],"clinical":[62],"trials,":[63],"which":[64],"high-potency":[68],"PBDs.":[69],"In":[70],"this":[71,89],"study,":[72],"we":[73],"evaluated":[74],"five":[75],"low-potency":[80,237],"PBD":[81,238],"SG3650.":[83],"The":[84,108],"relatively":[85],"low":[86],"clogD":[87],"for":[88,100,113,126],"agent":[90],"facilitated":[91],"higher":[92,173],"drug-to-antibody":[93],"ratio":[94],"(DAR)":[95],"conjugation":[96],"without":[97],"need":[99],"antibody":[101],"engineering":[102],"or":[103,218],"functionalization":[104],"drug.":[107],"rank":[109],"order":[110,125],"potency":[112],"DAR":[114,142,209],"2":[115,143,210],"site-specific":[116],"(conjugated":[118],"at":[119,172,220],"C239i":[121],"position)":[122],"matched":[123],"corresponding":[128,148],"free":[129,134],"vitro.":[132],"Despite":[133],"drug":[135],"SG3650":[136],"being":[137],"inactive":[138],"vivo,":[140],"derived":[145],"from":[146],"drug-linker":[149],"SG3584":[150,169,208],"showed":[151],"efficacy":[153],"solid":[155,246],"(anti-HER2)":[156],"hematologic":[158,244],"(anti-CD22)":[159],"xenograft":[160],"models.":[161],"Antitumor":[162],"activity":[163],"could":[164],"be":[165],"enhanced":[166],"by":[167,180,197],"conjugating":[168],"DARs":[174],"4":[176],"8":[178],"adjusting":[181],"dosing":[182],"schedule.":[184],"Higher-DAR":[185],"conjugates":[186],"were":[187],"stable":[188],"displayed":[190],"good":[191],"rat":[192],"pharmacokinetic":[193],"profiles":[194],"as":[195],"measured":[196],"ELISA":[198],"LC/MS-MS.":[200],"A":[201],"single":[202],"intravenous":[203],"dose":[204],"isotype":[206],"control":[207],"ADC":[211],"resulted":[212],"no":[214],"mortality":[215],"rats":[217],"monkeys":[219],"doses":[221],"up":[223],"25":[225],"30":[227],"mg/kg,":[228],"respectively.":[229],"These":[230],"findings":[231],"suggest":[232],"further":[234],"investigations":[235],"dimers":[239],"target":[243],"tumors":[247],"are":[248],"warranted.":[249]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":3}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2022-07-09T00:00:00"}